MX9803565A - A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein. - Google Patents

A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein.

Info

Publication number
MX9803565A
MX9803565A MX9803565A MX9803565A MX9803565A MX 9803565 A MX9803565 A MX 9803565A MX 9803565 A MX9803565 A MX 9803565A MX 9803565 A MX9803565 A MX 9803565A MX 9803565 A MX9803565 A MX 9803565A
Authority
MX
Mexico
Prior art keywords
casein
beta
recombinant human
phosphorylated recombinant
influenzae
Prior art date
Application number
MX9803565A
Other languages
Spanish (es)
Inventor
Pradip Mukerji
Jennifer M Thurmond
Lennart Hansson
Jeffrey H Baxter
Robert G Hards
Amanda Eun-Yeong Leonard
Steven M Anderson
Linda A Harvey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX9803565A publication Critical patent/MX9803565A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)

Abstract

A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human 'beta'-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human 'beta'-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human 'beta'-casein may also be administered as a throat spray or used in nose drops or a spray.
MX9803565A 1995-11-06 1998-05-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein. MX9803565A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55252995A 1995-11-06 1995-11-06

Publications (1)

Publication Number Publication Date
MX9803565A true MX9803565A (en) 1998-09-30

Family

ID=24205731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803565A MX9803565A (en) 1995-11-06 1998-05-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein.

Country Status (6)

Country Link
EP (1) EP0862450A2 (en)
JP (1) JP2000500141A (en)
AU (1) AU7610496A (en)
MX (1) MX9803565A (en)
NZ (1) NZ322369A (en)
WO (1) WO1997017085A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
CA2234680A1 (en) * 1995-11-06 1997-07-24 Abbott Laboratories Product for inhibition of attachment of h. influenzae to human cells
NZ574520A (en) 2002-11-27 2011-02-25 Dmi Biosciences Inc Use of casein which is at least 10% dephosphorylated for the treatment of diseases and conditions mediated by increased phosphorylation
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465109B (en) * 1989-10-30 1991-07-29 Bengt Andersson ANTIBACTERIAL COMPOSITION
US5795611A (en) * 1989-12-20 1998-08-18 Slattery; Charles W. Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
AU677230B2 (en) * 1992-09-22 1997-04-17 New Zealand Dairy Board A process for producing beta-casein enriched products
JPH10500101A (en) * 1994-05-26 1998-01-06 アボツト・ラボラトリーズ Inhibition of Haemophilus influenzae on human cells
EP0760674A1 (en) * 1994-05-26 1997-03-12 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
EP0812362A1 (en) * 1995-02-27 1997-12-17 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
CA2234680A1 (en) * 1995-11-06 1997-07-24 Abbott Laboratories Product for inhibition of attachment of h. influenzae to human cells

Also Published As

Publication number Publication date
WO1997017085A2 (en) 1997-05-15
AU7610496A (en) 1997-05-29
NZ322369A (en) 1999-11-29
JP2000500141A (en) 2000-01-11
EP0862450A2 (en) 1998-09-09
WO1997017085A3 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
ES2137948T3 (en) ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE.
EP0486425A3 (en) High acid system nutritional formulations
HU912064D0 (en) Process for the production of aralyphic n-substituted amino-alcane-phosphine acids and medical preparations containing them
GB2282140B (en) Purified forms of dnase
CA2151604A1 (en) Application of riluzole in the treatment of neurological lesions associated with traumas
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
HUT64086A (en) Process for producing gh-crystals
DE69331296D1 (en) Low caloric enteral formula for reducing diarrhea in tube-fed patients
ATE145554T1 (en) USE OF LIPIDS CONTAINING SHORT CHAIN FATTY ACIDS TO MAINTAIN THE INTEGRITY AND FUNCTION OF THE GASTROINTESTINAL CHANNEL
Larson et al. Frequency of eating as a factor in experimental dental caries
MX9803565A (en) A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein.
MX9803568A (en) Product for inhibition of attachment of h. influenzae to human cells.
GB8402573D0 (en) Oral formulation
HUT49284A (en) Process for production of medical compositions applicable "in loco" against androgene hairlessness
MY101747A (en) Dihydroorotic acids derivative, processes for preparing the same
MX9605829A (en) Inhibition of attachment of h. influenzae to human cells.
HU9201412D0 (en) Process for the enzymatic hydrolysis of carbonic acid derivatives
ES8407043A1 (en) Amino derivatives of substituted pyridazines, process for their preparation and medicines containing them.
MX9605830A (en) Inhibition of infection of mammalian cells by respiratory syncytial virus.
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
MX9701979A (en) Inhibition of human rotavirus infection.
GR3001209T3 (en) 4-methoxy-isophthalic acid derivative having a pharmacological activity in thromboembolic disorders and a process for the preparation thereof
Roe et al. Vocal stimulation early in life and infant vocal responsiveness to mother vs. stranger: A curvilinear relationship
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon